Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Announced details
Peptide drug derived from HMGB1, redasemtide; development code: S-005151
Applicable field (uses covered by this announcement)
Dystrophic epidermolysis bullosaAcute ischemic stroke
Relationship between the counterparty and the company
StemRIM Inc.4599
Relationship with the Company
Out-licensed by us to Shionogi & Co.,Ltd.
CounterpartyShionogi & Co.,Ltd.
Head office: Kita-ku, Osaka; Representative Director, Chairman and CEO: Teshirogi Isao (手代木 功)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
Shionogi & Co.,Ltd., “Fiscal 2025 Financial Results Briefing Materials,” dated 12 May 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | Peptide drug derived from HMGB1, redasemtide; development code: S-005151 |
| Counterparty | Shionogi & Co.,Ltd. |
| Counterparty overview | Head office: Kita-ku, Osaka; Representative Director, Chairman and CEO: Teshirogi Isao (手代木 功) |
| Relationship with the Company | Out-licensed by us to Shionogi & Co.,Ltd. |
| Applicable area | Dystrophic epidermolysis bullosa, Acute ischemic stroke |
| Source | Shionogi & Co.,Ltd., “Fiscal 2025 Financial Results Briefing Materials,” dated 12 May 2026 |
Items this document does not state (12)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because Shionogi & Co.,Ltd. disclosed its future research and development schedule.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.